Colocalization of somatostatin- and HLA-DR-like immunoreactivity in dendritic cells of psoriatic skin

Acta Dermato-Venereologica

Volumn 77, Issue 5, 1997, Pages 338-342

  Talme, T ^a   Schultzberg, M ^b   Sundqvist, K G ^a   Marcusson, J A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Immunohistochemistry; Langerhans' cells; Major histocompatibility complex class II; Psoriasis

Indexed keywords

SOMATOSTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; HLA SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PSORIASIS; REGULATORY MECHANISM;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOPSY; CELLS, CULTURED; DENDRITIC CELLS; DOUBLE-BLIND METHOD; FEMALE; HLA-DR ANTIGENS; HORMONE ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PSORIASIS; SKIN; SOMATOSTATIN;

EID: 0030959763     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Heng M, Kloss S. Cell interactions in psoriasis. Arch Dermatol 1985; 121: 881-887.
2. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555.
3. Morel P, Revillard J-P, Nicolas J-F, Wijdenes J, Rizova H, Thivolet J. Anti-CD4 monoclonal therapy in severe psoriasis. J Autoimmunol 1992; 5: 465-477.
4. Marcusson JA, Talme T, Wetterberg L, Johansson O. Peptide T-a new treatment for psoriasis? Acta Derm Venereol (Stockh) 1991; 71: 479-483.
5. Cerio R, Spaull JR, Wilson Jones E. Histiocytoma cutis: a tumour of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol 1989; 120: 197-206.
6. Morganroth G, Chan L, Weinstein G, Voorhees J, Cooper K. Proliferating cells in psoriatic dermis are comprised primary of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol 1991; 96: 333-340.
7. Wilson J, Foster D. Textbook of endocrinology. 8th edn. Philadelphia: Saunders Company, 1992.
8. Editorial. Octreotide steaming ahead. Lancet 1992; 339: 837-839.
9. Johansson O, Nordlind K. Immunohistochemical localization of somatostatin-like immunoreactivity in skin lesions from patients with urticaria pigmentosa. Virchows Arch 1984; 46: 155-164.
10. Johansson O, Vaalasti A. Immunohistochemical evidence for the presence of somatostatin-containing sensory nerve fibres in the human skin. Neurosci Lett 1987; 73: 225-230.
11. Weber G, Klughart G, Neidhardt N, Galle K, Frey H, Geiger A. Treatment of psoriasis with somatostatin. Arch Dermatol Res 1982; 272: 31-36.
12. Guilhou JJ, Boulanger A, Barneon G, Vic P, Meynadier J, Tardieau JC, et al. Somatostatin treatment of psoriasis. Arch Dermatol Res 1982; 274: 249-257.
13. Venier A, De Simone C, Forni L, Ghirlanda G, Uccioli L, Serri F, et al. Treatment of severe psoriasis with somatostatin: four years of experience. Arch Dermatol Res 1988; 280: S51-S54.
14. Matt LH, Kingston TP, Lowe NJ. Treatment of severe psoriasis with intravenous somatostatin. J Dermatol Treatm 1989; 181: 81-82.
15. Camisa C. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology. Arch Dermatol 1989; 1125: 407-412.
16. Pert C. The development of peptides and the promise of peptide T as treatment for AIDS. Mod Med 1989; 57: 44-53.
17. Johansson O, Hilliges M, Talme T, Marcusson JA. Somatostatin immunoreactive cells in psoriatic human skin during peptide T treatment. Acta Derm Venereol (Stockh) 1994; 74: 106-109.
18. Coons AH. Fluorescent antibody methods. In: Danielli JF, ed. General cytochemical methods. Vol 1. New York: Academic Press, 1958: 399-422.
19. Johnson DG, Nogueira Araujo GM. A simple method of reducing the fading of immunofluorescence during microscopy. J Immunol Meth 1981; 43(3): 349-350.
20. Tramu G, Pillez A, Leonardelli J. An efficient method of antibody elution for the successive or simultaneous location of two antigens by immunocytochemistry. J Histochem Cytochem 1978; 26: 322-324.
21. Baker B, Griffiths CEM, Lambert S, Powles A, Leonard J, Valdimarsson H. The effects of cyclosporin A on T lymphocyte and dendritic cell subpopulations in psoriasis. Br J Dermatol 1987; 116: 503-510.
22. Baker B, Lambert S, Powles AV, Valdimarsson H, Fry L. Epidermal DR+ T6-dendritic cells in inflammatory skin diseases. Acta Derm Venereol (Stockh) 1988; 68: 209-217.
23. Cerio R, Griffiths CEM, Cooper KD, Nickoloff BJ, Headington JT. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 1989; 212: 421-431.
24. Penneys N. Factor XIII expression in the skin: observation and a hypothesis. J Am Acad Dermatol 1990; 22: 484-488.
25. Eedy DJ. Neuropeptides in skin. Br J Dermatol 1993; 128: 597-605.
26. Payan D. The role of neuropeptides in inflammation. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: basic principles and clinical correlates. 2nd edn. New York: Raven Press, 1992: 177-192.
27. Farber E, Nickoloff BJ, Recht B, Fraki J. Stress, symmetry and psoriasis: possible role of neuropeptides. J Am Acad Dermatol 1986; 14: 305-311.
28. Farber E, Lanigan S, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis. Int J Dermatol 1990; 29: 418-420.
29. Naukkarinen A, Nickoloff BJ, Farber E. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol 1989; 92: 126-129.
30. Gazelius B, Brodin E, Olgart L, Panopoulos P. Evidence that substance P is a mediator of antidromic vasodilatation using somatostatin as a realease inhibitor. Acta Physiol Scand 1981; 113: 155-159.
31. Valdimarsson H, Baker B, Jonsdottir I, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145-149.
32. Bhatena SJ, Louie J, Schechter GP. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981; 30: 127-131.
33. Payan DG, Hess CA, Goetzl EJ. Inhibition by somatostatin of the proliferation of T lymphocytes and molt-4 lymphoblasts. Cell Immunol 1984; 84: 433-438.
34. Fais S, Annibale B, Boirivant M, Santoro A, Pallone F, Della Fave G. Effects of somatostatin on human intestinal lamina propria lymphocytes. J Neuroimmunol 1991; 31: 211-219.
35. Van Wyck JJ, Graves DC, Casella SJ, Jacobs S. Evidence from monoclonal antibody studies that insulin stimulates deoxyribonucleic acid synthesis through the type 1 somatomedin receptor. J Clin Endocrinol Metab 1985; 61: 639-643.
36. Misra P, Nickoloff BJ, Morhenn VB, Hintz RL, Rosenfeld RG. Characterization of insulin-like growth factor-1/somatomedin-C receptors on human keratinocyte monolayers. J Invest Dermatol 1986; 87: 264-267.
37. Clemmons DR. Multiple hormones stimulate the production of somatomedin by cultured human fibroblasts. J Clin Endocrinol Metab 1984; 58: 850-856.
38. Misra P, Nickoloff BJ, Morhenn VB, Hintz RL, Rosenfeld RG. Further characterization of the keratinocyte somatomedin-C/insulin-like growth factor 1 (SM-C/IGK-1) receptor and the biological responsiveness of cultured keratinocytes to SM-C/ IGF-1. Dermatologica 1988; 177: 265-273.
39. Nanney LB, Stoschek CM, Magid M, King LE. Altered (I-125) epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1986; 14: 305-311.
40. Reubi JC, Hunziker T. Absence of somatostatin receptors in psoriatic skin lesions. Arch Dermatol Res 1990; 282: 139-141.